Health Care

Humacyte’s bioengineered tissue tech faces steep financial challenges: negative P/E, volatile stock, and profit struggles threaten its biotech future.

Jiangsu Sihuan Bioengineering: a Chinese biotech leader with $4.25 B market cap, 52‑week high stock price, and a future‑focused R&D strategy to boost profitability and industry impact.

Jiangsu Hengrui Pharmaceuticals gains CFDA clinical‑trial approval, positioning its new oncology candidate to boost shares and capture a growing soft‑tissue sarcoma market.

Discover how Hedera Group AB’s partnership with String Metaverse is reshaping healthcare staffing with blockchain, DeFi tokenization, and crypto‑backed cards.

Upcoming Aditxt shareholder meeting: vote on a reverse stock split and adjournment to boost Nasdaq compliance and market confidence.

Hyperliquid’s validator‑governed prediction markets could redefine crypto trading, marrying treasury strategy with decentralized outcome betting—are they a breakthrough or a risk?

Amgen’s biotech strategy fuels growth—expanding biologics, scaling manufacturing, and advancing clinical trials to strengthen market leadership and investor confidence.

Assertio Holdings faces a double‑edged future: potential Russell Microcap upgrade could lift shares, while a new shareholder‑rights investigation may reshape its governance and capital structure.

Hansa Biopharma’s Phase III ConfIdeS results on the enzyme imflidas will be presented as a late‑breaking abstract at the American Transplant Congress, potentially advancing kidney transplant therapy and regulatory prospects.

Hemostemix Inc. battles financial turbulence while pioneering blood‑derived cell therapies for severe medical disorders, sparking investor debate over its future viability.